双鹭药业：股东梁淑洁计划减持公司股份不超过约38万股

Group 1 - The core point of the announcement is that Liang Shujie, a director and board secretary of Shuanglu Pharmaceutical, plans to reduce her shareholding by up to approximately 380,000 shares, which represents no more than 0.0365% of the company's total share capital, within three months after the pre-disclosure announcement [1] - As of the announcement date, Liang Shujie holds about 1.5 million shares, accounting for 0.1461% of the total share capital of Shuanglu Pharmaceutical [1] - For the first half of 2025, Shuanglu Pharmaceutical's revenue composition shows that the pharmaceutical industry accounts for 97.48%, while other businesses account for 2.52% [1] Group 2 - The current market capitalization of Shuanglu Pharmaceutical is 7.7 billion yuan [2]